From Individual Potential To The Power Of An Alliance Of Territories

From Individual Potential To The Power Of An Alliance Of Territories

No one doubts, at this point, that the personalized medicine It constitutes one of the sectors related to health in which technology, research and innovation will play a more important role.

There is no region that is not working, in a more or less advanced way, to provide its health system – whose management is transferred to the regional governments – with all the necessary wicks so that this sector is a benchmark in the medium and long term.

However, not all autonomies are following the same strategy. There are two speeds, that of those who have been a benchmark for some time, who choose to maintain this collaborative but individual work, and that of those regions that seek to gain potential by forging alliances.


[La plataforma de fabricación celular que lleva a Asturias a un nuevo nivel en el sector de la medicina personalizada]

In the first group we find, evidently, Navarre. Its internationally recognized genomic technology or the opening of the Massive Sequencing Center in the Autonomous Community -the second publicly owned in all of Spain- are sufficient reasons for the work that the region has been developing in this sector to be taken into account.

There are other regions that, although they had not been characterized by their notoriety in personalized medicine, have given a boost to their strategies individually. This is the case of Asturias, which, as D+I explained a few days ago, has formalized the purchase of a cell manufacturing platform that will allow it to research and develop its own and personalized drugs.

The fact that these regions are working individually does not obviously mean that they do not have open lines of collaboration with other territories.

What happens -and therein lies the difference- is that other autonomous communities, with the support of the central government, have decided to join forces.

[Tecnología genómica y enfermedades raras: Navarra se vende en Brasil como líder en medicina personalizada]

This week it has been presented in Castilla la Mancha a research project on biotechnology applied to health, in which seven regions participate, including Castilian-La Mancha and Andalusia, Aragon, Catalonia, Extremadura, the Basque Country and Galicia.

This is a unique research project that will help create a national network of personalized medicine.

This project, entitled ‘Development of tools for diagnosis, prognosis and advanced or directed therapies in personalized medicine’, is coordinated by the Ministry of Science and Innovation and is part of the Complementary Plans charged to the funds of the Plan of Recovery, Transformation and Resilience.

The Minister of Education, Culture and Sports, Rosa Ana Rodríguez, has highlighted that thanks to this initiative different research programs will be developed “that have the objective of seeking solutions, from Science, to improve treatments and quality of life of patients with serious illnesses.

Supercomputing, robotics or nanotechnology

Thus, it has specified that “through this project a large national network in personalized medicine will be created that will allow the treatment of some serious illnesses to be adapted to the specific characteristics of each patient, with which a more effective treatment is achieved and with fewer side effects. And Castilla-La Mancha, thanks to this initiative, will be leading projects in this network”.

To do this, elements such as biomedicine, artificial intelligence, supercomputing, robotics, sensors and nanotechnology will be combined to design and produce new systems and devices for diagnosis, prognosis and therapy.

“The goal is that within two or three years we can have a range of drugs that can help in these treatments,” the counselor assured.

The project takes advantage of the importance of “institutional collaboration” and research groups belonging to the UCLM participate in it, such as the Associated Unit Neurodeath, Computer Engineering, Faculty of Medicine of Albacete and Faculty of Environmental Sciences and Biochemistry, and SESCAM , the University Hospital of Albacete and the University Hospital of Toledo.

Castilla-La Mancha also provides cohorts of patients (patient groups that are part of a clinical trial) in two important pathologies: one with persistent COVID and the other with non-alcoholic fatty liver. The possible incorporation of additional cohorts is planned.

The project has six lines of action: BERM Platform (microscopy); Implementation and analysis of databases in precision medicine; Drug screening platform and analysis of drug-target interactions; Development of biological models of disease; Development of nanopharmaceuticals (coordinated by Castilla-La Mancha) and Advanced Therapies and Medical Robotics. Castilla-la Mancha research groups participate in all lines of action.

Follow the topics that interest you



Leave a Reply

Your email address will not be published.

9 + 1 =